The median overall survival in all 16 patients with IDH1 wild-type high-grade gliomas that harbored actionable mutations and received genotype-matched targeted therapies, was 14.72 months with a median progression-free survival of 7.37 months (Figure 4). This evidence concerns the gene IDH1 and glioma.